Q1 EPS Estimates for MiMedx Group Boosted by Northland Capmk

MiMedx Group, Inc. (NASDAQ:MDXG) – Research analysts at Northland Capmk increased their Q1 2025 earnings per share estimates for MiMedx Group in a report issued on Thursday, February 27th. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.06 for the quarter, up from their previous forecast of $0.05. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.08 EPS and FY2026 earnings at $0.38 EPS.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million.

A number of other analysts have also issued reports on MDXG. StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a research note on Thursday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.40.

MiMedx Group Stock Performance

MDXG opened at $8.14 on Friday. MiMedx Group has a 52-week low of $5.47 and a 52-week high of $10.14. The company has a market cap of $1.20 billion, a PE ratio of 14.80 and a beta of 1.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a 50-day moving average of $8.74 and a 200-day moving average of $7.68.

Institutional Trading of MiMedx Group

Several hedge funds have recently modified their holdings of the stock. Blue Trust Inc. acquired a new stake in MiMedx Group in the third quarter worth about $30,000. Allspring Global Investments Holdings LLC lifted its holdings in MiMedx Group by 1.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company’s stock valued at $1,082,000 after buying an additional 1,822 shares during the period. Farther Finance Advisors LLC boosted its stake in MiMedx Group by 88.6% in the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock valued at $145,000 after acquiring an additional 11,557 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of MiMedx Group by 299.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after purchasing an additional 770,744 shares during the last quarter. Finally, Cannon Global Investment Management LLC grew its stake in shares of MiMedx Group by 47.1% during the third quarter. Cannon Global Investment Management LLC now owns 25,000 shares of the company’s stock worth $148,000 after purchasing an additional 8,000 shares during the period. 79.15% of the stock is owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.